InsuletMEX:PODD 75 EBIT per Share is MXN121.04 as of Mar. 2026. GuruFocus rates MEX:PODD with a GF Score™ of 75/100 and a GF Value™ of MXN8,168.01 (Significantly Undervalued). Among 690 Medical Devices & Instruments companies, Insulet ranks better than 98.99% on this metric.
Insulet's EBIT per Share for the
three
months ended in Mar. 2026 was MXN32.80.
Its EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 was MXN121.04.
During the past 12 months, the average EBIT per Share Growth Rate of Insulet was 56.20% per year.
During the past 3 years, the average EBIT per Share Growth Rate was 130.50% per year.
During the past 5 years, the average EBIT per Share Growth Rate was 52.80% per year.
Please click Growth Rate Calculation Example (GuruFocus) to see how GuruFocus calculates Wal-Mart Stores Inc (WMT)'s revenue growth rate. You can apply the same method to get the EBIT per Share growth rate using EBIT per Share data.
The historical rank and industry rank for Insulet's EBIT per Share or its related term are showing as below:
MEX:PODD'
s 3-Year EBIT Growth Rate Range Over the Past 10 Years
Min: -18.2 Med: 31.95 Max: 130.5
Current: 130.5
During the past 13 years, the highest 3-Year average EBIT per Share Growth Rate of Insulet was 130.50% per year. The lowest was -18.20% per year. And the median was 31.95% per year.
MEX:PODD's 3-Year EBIT Growth Rate is ranked better than 98.99% of 690
companies
in the Medical Devices & Instruments industry
Industry Median: 9.5
vs MEX:PODD: 130.50
Insulet's EBIT for the
three
months ended in Mar. 2026 was MXN2,303 Mil.
Insulet (MEX:PODD) EBIT per Share Explanation
EBIT is a company's earnings before interest and tax expenses are deducted. It measures a company's profit generates from operating, ignoring tax burden and capital structure. As the tax expense are not deducted, EBIT is helpful when comparing companies in the same industry but with different tax situations. Also, the interest expense are included in EBIT, making it useful to compare companies that have high interest expenses due to large amount of debt.
Insulet EBIT per Share Related Terms
Insulet EBIT per Share Historical Data
* Premium members only.
The historical data trend for Insulet's EBIT per Share can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
EBIT per Share for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was MXN121.04
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Insulet (MEX:PODD) has a EBIT per Share of MXN121.04 as of Mar. 2026. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Insulet and its competitors. According to the industry distribution chart, Insulet ranks #7 out of 690 companies in the Medical Devices & Instruments industry, placing it in the top 1%.
Is Insulet's EBIT per Share too high?
Insulet's current EBIT per Share is MXN121.04. Based on the distribution chart, Insulet ranks #7 out of 690 companies in the Medical Devices & Instruments industry, which is in the top quartile — a strong position relative to peers. Overall, Insulet has a GF Score™ of 75/100 and is considered Significantly Undervalued, reflecting its overall financial health beyond just this single metric.
How does Insulet's EBIT per Share compare to GMED and PEN?
According to the Medical Devices & Instruments industry distribution chart, Insulet ranks #7 out of 690 companies for EBIT per Share. This places Insulet in the top 1% of its industry — outperforming the majority of peers. The industry median EBIT per Share is 9.50. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good EBIT per Share for a Medical Devices & Instruments company?
The median EBIT per Share among Medical Devices & Instruments companies is 9.50, based on 690 companies in the industry. Companies in the top quartile (top 25%) have a EBIT per Share significantly above this median, while those in the bottom quartile fall well below. However, EBIT per Share should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high EBIT per Share mean?
A high EBIT per Share can signal that a stock is expensive relative to its fundamentals. EBIT per Share is the amount of Earnings Before Interest and Taxes per outstanding share of the company's stock. View historical data on Insulet and its competitors. For the Medical Devices & Instruments industry, the median EBIT per Share is 9.50 — values significantly above this may indicate overvaluation, while values below may suggest a bargain or underlying issues. Insulet's current EBIT per Share is MXN121.04. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Insulet stock overvalued right now?
Based on GuruFocus' analysis, Insulet (MEX:PODD) is currently considered Significantly Undervalued. The stock's GF Value™ is MXN8,168.01, compared to a current price of MXN2,780.00 — trading 66% below its estimated fair value. The current EBIT per Share is MXN121.04. Insulet's overall GF Score™ is 75/100. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is EBIT per Share calculated?
EBIT per Share is calculated from a company's financial statements. For Insulet (MEX:PODD), the current EBIT per Share is MXN121.04 as of Mar. 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Is Insulet (MEX:PODD) Overvalued in 2026?
Based on GuruFocus' analysis, Insulet stock appears to be undervalued.
The current stock price of MXN2,780.00 is trading 66% below its estimated GF Value™ of MXN8,168.01.
GuruFocus considers Insulet to be Significantly Undervalued.
Key valuation signals for MEX:PODD:
EBIT per Share: MXN121.04
GF Value™: MXN8,168.01 vs. price of MXN2,780.00 (66% below fair value)
No single metric tells the full story. See the MEX:PODD stock analysis page for a complete view including 30-year financials, guru trades, and insider activity.
Insulet was founded in 2000 with the goal of making continuous subcutaneous insulin infusion therapy for diabetes easier to use. The result was the Omnipod system, which consists of a small disposable insulin infusion device that can be operated through a smartphone to control dosage. Since the Omnipod was approved by the US Food and Drug Administration in 2005, more than 600,000 insulin-dependent diabetic patients are using it worldwide.
75GF Score
Get the complete analysis for MEX:PODD
EBIT per Share is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
MEX:PODD has been successfully added to your 
